• 09.01.2020 – 09:03

  Technische Universität München

  Gene network helps to turn white fat into beneficial calorie burning fat

  TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/ High resolution images: https://mediatum.ub.tum.de/1524726 NEWS RELEASE A new approach to treating overweight and obesity Gene network helps to turn white fat into beneficial calorie ...

  more

• 18.12.2019 – 14:07

  Grünenthal Group

  Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin) 8% Patch for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

  Morristown, N.J. (ots) - · PDUFA date set for July 19, 2020 · If approved, QUTENZA would be the first topical treatment with a TRPV1 agonist indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Averitas Pharma, Inc., a subsidiary of GRT US Holding, Inc. and member of the ...

  more

• 04.12.2019 – 09:01

  ForaCare Suisse AG

  ForaCare Suisse AG Launches "Lab in the Pocket" Technology

  ST. GALLEN, Switzerland (ots) - Innovative FORA 6 GTel Capability Provides 6 Tests with Single Device, SIM Direct-to-Telehealth Connectivity ForaCare Suisse AG announced the launch of its FORA 6 GTel multi-functional monitoring device with its new "Lab in the Pocket" technology (available on the GTel model and FORA 6 Series products). The innovative 6-in-1 monitoring technology provides seamless 3G/4G data transmission of ...

  more

• 19.11.2019 – 13:38

  Gerresheimer AG

  New Focus in Project Portfolio of Gerresheimer Subsidiary Sensile Medical

  Dusseldorf, Germany (ots/PRNewswire) - - SQ Innovation and Gerresheimer sign partnership for micro pumps for heart failure treatment - Sanofi terminates development project for micro pumps for patients with diabetes - Further projects with pharma customers for various therapy areas for the micro pump started Sensile Medical, a subsidiary of Gerresheimer AG, has signed ...

  more

• 19.11.2019 – 12:00

  Gerresheimer AG

  New focus in project portfolio of Gerresheimer subsidiary Sensile Medical

  Duesseldorf (ots) - - SQ Innovation and Gerresheimer sign partnership for micro pumps for heart failure treatment - Sanofi terminates development project for micro pumps for patients with diabetes - Further projects with pharma customers for various therapy areas for the micro pump started Sensile Medical, a subsidiary of Gerresheimer AG, has signed a contract with the ...

  more

• 17.09.2019 – 15:45

  Novo Nordisk A/S

  Ozempic® Offers Superior Reductions in HbA1c and Body Weight Compared to Both Victoza® and Canagliflozin in People With Type 2 Diabetes

  Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk announced today the results from two Ozempic® (once-weekly semaglutide 1.0 mg) head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which showed: - Ozempic® was superior to treatment with the SGLT-2 inhibitor canagliflozin (300 mg) in reducing HbA1c and ...

  more

• 06.11.2018 – 09:02

  Primary Care Diabetes Europe (PCDE)

  Primary Care Diabetes Europe Issues Call to Action Against Clinical Inertia in the Treatment of Type-2 Diabetes

  Ekeren, Belgium (ots/PRNewswire) - Research identifies lack of primary care physician adherence to treatment guidelines among the challenges to optimal care for patients with type-2 diabetes Primary Care Diabetes Europe (PCDE) today issued a call to action challenging primary care physicians and other healthcare ...

  more

• 28.09.2018 – 10:01

  Novo Nordisk A/S

  International Diabetes Federation (IDF) Global Survey Reveals 2 in 3 People With Type 2 Diabetes Have Cardiovascular Disease Risk Factors and/or Have Experienced a Cardiovascular Event

  Bagsværd, Denmark (ots/PRNewswire) - - Cardiovascular disease (CVD) is the leading cause of disability and death in people with type 2 diabetes[1] - Despite the high incidence, 1 in 4 people with type 2 diabetes have never discussed, or cannot recall discussing, CVD risk factors with a doctor[2] - First-ever global ...

  more